By vgreene, 10 October, 2020 Treatment of COVID-19 Patients With Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality; <a href=https://ajp.amjpathol.org/article/S0002-9440(20)30370-9/fulltext><b><u>full-text <i>Am J Pathol</i> article</u></b></a>
By vgreene, 10 October, 2020 Convalescent Plasma or Hyperimmune Immunoglobulin for People With COVID‐19: A Living Systematic Review (Cochrane); <a href=https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub2/full><b><u>access <i>Cochrane Library</i> article</u></b></a
By vgreene, 10 October, 2020 <b>Study considerations:</b> non-comparative; safety data only, no efficacy data; some reported SAEs may represent natural dz progression; other transfusion-related theoretical risks not reported; detailed training of study personnel lacking; web-based ca
By vgreene, 10 October, 2020 Outcomes w/in 7 days of tx completion: 1,136 SAEs incl thromboembolic/thrombotic event (n=87), hypotensive events requiring pressor support (n=406), cardiac events (n=643); majority of thromboembolic/thrombotic complications (n=55) and cardiac events (n=5
By vgreene, 10 October, 2020 Outcomes w/in 1st 4h of transfusion: 146 (<1%) serious adverse events (SAEs) classified as transfusion rxn incl transfusion-assoc circulatory overload (n=37), transfusion-related acute lung injury (n=20), severe allergic transfusion rxn (n=26); 13 transfu
By vgreene, 10 October, 2020 Multicenter open-label Expanded Access Program; 20,000 hospitalized pts (60% of pts over 60y, 61% male, 58% ICU pts) w/ severe or life-threatening COVID-19 received ABO-compatible COVID-19 convalescent plasma 200-500 mL IV per protocol
By vgreene, 10 October, 2020 Safety Update COVID 19 Convalescent Plasma in 20 000 Hospitalized Patients
By vgreene, 10 October, 2020 <a href=https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1><b><u>Access pre-print <i>medRxiv</i> article</u></b></a>
